ERBB2 and non-small cell lung carcinoma: A phase II study launched by the Eastern Cooperative Oncology Group (ECOG) evaluated the efficacy of combining carboplatin, paclitaxel and trastuzumab in advanced NSCLC patients with HER-2/neu positivity (1+ to 3+).